Ticker LaunchCanada to US · Cross-listing
BELLUS Health Inc.
BELLUS Health Inc., a Quebec-based company, cross-listed on Nasdaq on Sep 3, 2019, registering its securities on Form 8-A12B.
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and other hypersensitization disorders. Its product candidate BLU-5937 is a twice-daily oral P2X3 receptor antagonist being developed for chronic cough and chronic pruritus.
- Type
- Cross-listing
- US exchange
- Nasdaq
- Listed
- Sep 3, 2019
- Province
- Quebec
- Registration form
- 8-A12B
- Security
- Common shares
- Sector
- Biotech & pharma
More on this listing for subscribers
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration (8-A12B) Sep 3, 2019
- Offering document
- All filings on EDGAR CIK 1259942
Other Canadian companies listing in the US
- Liminal BioSciences Inc.Nasdaq · Nov 12, 2019
- Dirtt Environmental Solutions LtdNasdaq · Sep 20, 2019
- Equinox Gold Corp.NYSE American · Sep 10, 2019
- Profound Medical Corp.Nasdaq · Aug 29, 2019
- Viemed Healthcare, Inc.Nasdaq · Jul 10, 2019
- Maverix Metals Inc.NYSE American · Jun 7, 2019